Lilly volunteer service day blooms into citywide effort
More than 60 companies plan to participate in the three-day Indy Do Day volunteer marathon, which kicks off Thursday in conjunction with Eli Lilly and Co.’s Global Day of Service.
Eli Lilly and Co.
Articles
Financial pressures stretching Lilly
In a series of presentations, Lilly executives stretched themselves in four directions at once to convince investors and stock analysts that the company will bend but not break next year, and then snap back stronger than ever in 2015.
Lilly, other drugmakers itching to find new psoriasis treatment
Psoriasis is linked to higher rates of heart disease and diabetes, and a third of patients also develop a form of arthritis. About 125 million people worldwide have the skin condition, including 7.5 million Americans.
Lilly to buy back $5B as sales goal harder to reach
Eli Lilly and Co. said Thursday that meeting its sale target will be a challenge. It plans to repurchase $5 billion in shares and introduce new diabetes drugs to help navigate through patent losses. Another immediate hurdle: Obamacare.
Lilly shares dip after cancer treatment misses goal
Eli Lilly said a potential breast cancer treatment missed its main goal in a late-stage study. However, the drugmaker will seek approval to use the treatment in stomach cancer patients after ramucirumab performed better in a separate study.
Lilly bets quality over quantity will pay off in diabetes battle
Eli Lilly and Co. is counting on the quality of a diversified product portfolio over boosting its sales forces to grab a bigger slice of the $22 billion U.S. diabetes market, a difference in strategy to some of its rivals.
Alzheimer’s targeted in $45M government study grant
Part of the funding will go to an existing study of drugs from Eli Lilly and Co. and others to see whether they can ward off the disease in people who inherited genes that predestine them to get Alzheimer’s.
Drugmakers turn up marketing efforts in diabetes market
With a half-dozen new products lined up for approval within two years, the fight to win the growing $22 billion U.S. diabetes market is expected to intensify.
China bribery probe leading to tough drug market, CEO says
Drugmakers under investigation for bribery have stopped promoting products in China, and physicians in some hospitals no longer want to meet sales representatives. Eli Lilly is among the drugmakers in China facing allegations.
Lilly cites ‘deep concerns’ over China kickback allegations
Eli Lilly and Co. said it is investigating allegations its employees paid Chinese doctors at least $4.9 million in bribes and kickbacks to promote the sales of two diabetes drugs.
Lilly lung cancer drug raises patient survival in trial
If approved, the drug would be a potent boost to Lilly’s product portfolio. It would also mean a critical new therapy for a cancer that’s proven difficult to treat.
Lilly’s new strategy built around head-to-head drug trials
Lilly has set up not one, not two, but five head-to-head trials of its experimental drug dulaglutide against other leading diabetes therapies. So far, dulaglutide’s record is four wins, no losses.
PROXY CORNER: Eli Lilly and Co.
Indianapolis-based Eli Lilly and Co. discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
Lilly shares rise after drugmaker reports solid second quarter
Strong sales and penny-pinching helped Eli Lilly and Co. beat Wall Street’s expectations in the second quarter, leading the company to raise its profit forecast for the year.
Lilly freezes pay for workers, executives
The pay freeze will save $400 million through 2016, said a spokesman for the Indianapolis-based company. Lilly won’t give pay raises to executives, supervisors or most employees. Some bonuses will also be reduced.
Lilly aims potential Alzheimer’s drug at early patients
The trial of 2,100 patients, called Expedition III, will use new measures of cognitive function, such as the ability to do tasks like cooking or driving, or remembering words after a delay.
Lilly drug for Alzheimer’s gets limited Medicare coverage
Lilly officials said they will push ahead with the first-of-a-kind imaging chemical, despite the mostly negative ruling by Medicare officials.
Lilly’s Lechleiter back at helm after health scare
Eli Lilly and Co. Chairman and CEO John Lechleiter is back to full-time work after taking a leave in May to have surgery for a dilated aorta, the company announced Monday morning.
Miami man pleads guilty to $90M Lilly drug heist
Thieves broke into the Connecticut warehouse of Indianapolis-based Eli Lilly and Co. in 2010 by scaling an exterior wall and cutting a hole in the roof. They lowered themselves to the floor and disabled alarms before using a forklift to load pallets of drugs into a getaway vehicle.
Feds mull covering Alzheimer’s test that uses Lilly’s Amyvid
The $3,000 test for the first time accurately identifies the signature brain plaques of the debilitating disease.